Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial

Table 2 Outcomes of patients with and without sepsis*

	Patients with sepsis			Patients without sepsis
Outcome variable	DEX (n = 31)	LZ (n = 32)	Adjusted P value**	DEX (n = 20)	LZ (n = 19)	Adjusted P value**
Duration of brain organ dysfunction
Delirium/coma-free days**	6.1 (4.3)	2.9 (3.2)	0.005	6 (4.7)	5.5 (3.6)	0.97
Delirium-free days^†	8.1 (3.1)	6.7(2.9)	0.06	8.1 (3.5)	7.9 (2.8)	0.80
Coma-free days^ǂ	9.4 (2.9)	5.9 (4.2)	<0.001	8.9 (4)	8.8 (2.6)	1
Other clinical outcomes
MV-free days^‡	15.2 (10.6)	10.1 (10.3)	0.03	12.8 (11.5)	17.2 (10)	0.15
ICU days	13.4 (15.1)	12.2 (9.8)	0.81	14.9 (16.5)	10.4 (8.9)	0.28
28-day mortality	16%	41%	0.03	19%	5%	0.21

Mean (standard deviation) unless otherwise noted.
DEX, dexmedetomidine; LZ, lorazepam; MV, mechanical ventilation.
* Adjusted P value obtained from the bootstrap multiple linear regression that calculated a difference in mean for each outcome between the two treatment groups, adjusting for age, severity of illness, use of drotrecogin alfa (activated) within 48 hours of enrollment, sepsis, treatment group, and a treatment group by sepsis interaction.
**Indicates the number of days alive without delirium or coma from study day 1 to 12.
†Indicates the number of days alive without delirium from study day 1 to 12.
ǂIndicates the number of days alive without coma from study day 1 to 12.
‡Indicates the number of days alive breathing without assistance of the ventilator from study day 1 to 28.

ISSN: 1364-8535